Research Area: Cardiovascular Disease
Biological Activity:
Ozagrel is a potent and selective thromboxane A2 synthetase inhibitor with an IC50 of 4 nM. It does not inhibit prostacyclin (PGI2) synthetase, cyclooxygenase or PGE2 isomerase (IC50 > 1 mM). Inhibits platelet aggregation in vitro and arachidonate-induced arterial contraction in vivo. The beneficial effects of TXAS inhibition by ozagrel include improved motor coordination after experimental stroke and antihypertensive effects in spontaneously hypertensive rats. [1][2][3]References on Ozagrel[1] http://en.wikipedia.org/wiki/Ozagrel, , [2] Jpn J Pharmacol., 1986 Jul, 41(3):393-401.[3] J Urol., 1987 Mar, 137(3):571-6.